Literature DB >> 10229148

In vitro and in vivo photosensitizing capabilities of 5-ALA versus photofrin in vascular endothelial cells.

C J Chang1, C H Sun, L H Liaw, M W Berns, J S Nelson.   

Abstract

BACKGROUND AND
OBJECTIVE: The objective of the present study was to evaluate the feasibility of photodynamic therapy (PDT) for complicated hemangiomas. The photosensitizing activities of 5-aminolevulinic acid (5-ALA) and Photofrin were evaluated in vitro with human dermal microvascular endothelial cells (MEC) and in vivo with the chicken cox comb. STUDY DESIGN/
MATERIALS AND METHODS: The in vitro absorption and photosensitizing activities of 5-ALA and Photofrin were examined in a MEC culture system. The percentages of MEC killed by different drug concentrations at a wavelength of 630 nm were measured by either live/dead or lactate dehydrogenase-released assays. Similarly, the in vivo biological activities of 5-ALA and Photofrin exposed to different total light dosages at 630 nm were studied by determining the amount of necrosis produced in chicken combs.
RESULTS: MEC incubated with 5-ALA at a concentration of 35 microg/ml and exposed to laser light at 630 nm at a power density of 100 mW/cm2 showed a 50% cell kill. MEC incubated with Photofrin at a concentration of 3.5 microg/ml and exposed to laser light at 630 nm at a power density of 100 mW/cm2 showed a 50% cell kill. Chicken combs that received 200 mg/kg of 5-ALA exposed to laser light at 630 nm at a power density of 100 mW/cm2 had an injury depth of 362.5+/-27.6 microm at histologic examination. Combs exposed to a power density of 100 or 120 mW/cm2 showed injury depths of 732.5+/-29.1 and 792.5+/-36.0 microm, respectively. Chicken combs that received 2.5 mg/kg of Photofrin exposed to laser light at 630 nm at a power density of 80 mW/cm2 had an injury depth of 535.6+/-22.3 microm at histologic examination. Combs exposed to a power density of 100 or 120 mW/cm2 showed injury depths of 795.8+/-32.5 and 805.2+/-49.1 microm, respectively.
CONCLUSION: Both 5-ALA and Photofrin have the capability to destroy MEC in vitro and vasculature in vivo. However, Photofrin achieved a higher degree of cell kill and tissue destruction at lower drug concentrations and at lower power densities.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10229148     DOI: 10.1002/(sici)1096-9101(1999)24:3<178::aid-lsm2>3.0.co;2-w

Source DB:  PubMed          Journal:  Lasers Surg Med        ISSN: 0196-8092            Impact factor:   4.025


  5 in total

1.  Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.

Authors:  Daniela A Bota; Daniela Alexandru; Stephen T Keir; Darell Bigner; James Vredenburgh; Henry S Friedman
Journal:  J Neurosurg       Date:  2013-10-04       Impact factor: 5.115

2.  Pyogenic granuloma in a patient with psoriasis successfully treated by 5-aminolevulinic acid photodynamic therapy: A case report.

Authors:  Juan Liu; Bing-Rong Zhou; Fei Yi; Hong-Jin Wu; Jia-An Zhang; Dan Luo
Journal:  Exp Ther Med       Date:  2015-11-27       Impact factor: 2.447

3.  Photodynamic therapy can induce a protective innate immune response against murine bacterial arthritis via neutrophil accumulation.

Authors:  Masamitsu Tanaka; Pawel Mroz; Tianhong Dai; Liyi Huang; Yuji Morimoto; Manabu Kinoshita; Yasuo Yoshihara; Koichi Nemoto; Nariyoshi Shinomiya; Suhji Seki; Michael R Hamblin
Journal:  PLoS One       Date:  2012-06-26       Impact factor: 3.240

Review 4.  Molecular and Metabolic Mechanisms Underlying Selective 5-Aminolevulinic Acid-Induced Fluorescence in Gliomas.

Authors:  Jeffrey I Traylor; Mark N Pernik; Alex C Sternisha; Samuel K McBrayer; Kalil G Abdullah
Journal:  Cancers (Basel)       Date:  2021-02-02       Impact factor: 6.639

5.  Phototheranostics of Cervical Neoplasms with Chlorin e6 Photosensitizer.

Authors:  Aida Gilyadova; Anton Ishchenko; Artem Shiryaev; Polina Alekseeva; Kanamat Efendiev; Radmila Karpova; Maxim Loshchenov; Victor Loschenov; Igor Reshetov
Journal:  Cancers (Basel)       Date:  2022-01-02       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.